Zoetis Earns $1.19 per Share for Q2.

This morning, Zoetis (ZTS) reported very good earnings for its fiscal Q2. Zoetis made $1.19 per share. That’s up 34% from last year and it beat estimates of $1.08 per share. Quarterly revenue rose 26% to $1.9 billion.

“We achieved strong results once again this quarter with 22% operational revenue growth and 28% growth in adjusted net income, driven by our petcare parasiticides, key dermatology products, vaccines and diagnostics,” said Kristin Peck, Chief Executive Officer of Zoetis. “Our triple combination parasiticide Simparica Trio® continues exceeding our launch expectations and strengthening our overall position in this competitive market, and we remain very positive about further uptake of our petcare innovations in monoclonal antibodies and diagnostics.”

“We are raising guidance for revenue and adjusted net income for the full year to reflect our confidence in Zoetis and the underlying growth drivers of our business, even while we continue to expect more modest growth rates in the second half of 2021. We remain in a strong position to invest both internally and externally in the innovations, market expansion and direct-to-consumer promotions that can support future growth,” said Peck.

Zoetis divides its business into two segments, U.S. and International. The U.S. segment saw its revenues rise 22% to $1.0 billion. The International segment increased 31% to $924 million.

Now for the best news. Zoetis sees full-year revenue ranging between $7.625 and $7.7 billion. For earnings, the company now sees 2021 earnings between $4.47 and $4.55 per share.

This is the second time Zoetis has raised its earnings forecast this year. The original range was $4.36 to $4.46 per share. Three months ago, ZTS lifted it to $4.42 to $4.51 per share.

Posted by on August 5th, 2021 at 11:16 am


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.